Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma
DOI:
https://doi.org/10.2340/actadv.v102.1433Keywords:
anemia, cobimetinib, melanoma, Stevens-Johnson syndrome, pembrolizumab, vemurafenibAbstract
Abstract is missing (Short communication)
Downloads
References
Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019; 4: e000491.
https://doi.org/10.1136/esmoopen-2019-000491 DOI: https://doi.org/10.1136/esmoopen-2019-000491
O'Reilly A, Larkin J. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert Rev Anticancer Ther 2017; 17: 647-655.
https://doi.org/10.1080/14737140.2017.1341315 DOI: https://doi.org/10.1080/14737140.2017.1341315
Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs). J Eur Acad Dermatol Venereol 2021; 35: 607-614.
https://doi.org/10.1111/jdv.16894 DOI: https://doi.org/10.1111/jdv.16894
Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 2017; 28: 1137-1144.
https://doi.org/10.1093/annonc/mdx040 DOI: https://doi.org/10.1093/annonc/mdx040
Lamiaux M, Scalbert C, Lepesant P, Desmedt E, Templier C, Dziwniel V, et al. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Res 2018; 28: 451-457.
https://doi.org/10.1097/CMR.0000000000000472 DOI: https://doi.org/10.1097/CMR.0000000000000472
Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer 2019; 125: 884-891.
https://doi.org/10.1002/cncr.31889 DOI: https://doi.org/10.1002/cncr.31889
Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G, et al. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? J Eur Acad Dermatol Venereol 2016; 30: 178-179.
https://doi.org/10.1111/jdv.12685 DOI: https://doi.org/10.1111/jdv.12685
Tahseen AI, Patel NB. Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. JAAD Case Rep 2018; 4: 930-933.
https://doi.org/10.1016/j.jdcr.2018.08.003 DOI: https://doi.org/10.1016/j.jdcr.2018.08.003
Pinard C, Mignard C, Samain A, Duval-Modeste A-B, Joly P. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD Case Rep 2017; 3: 532-533.
https://doi.org/10.1016/j.jdcr.2017.06.027 DOI: https://doi.org/10.1016/j.jdcr.2017.06.027
Broman KK, Dossett LA, Sun J, Eroglu Z, Zager JS. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin Drug Saf 2019; 18: 381-392.
https://doi.org/10.1080/14740338.2019.1607289 DOI: https://doi.org/10.1080/14740338.2019.1607289
Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer 2019; 7: 4.
https://doi.org/10.1186/s40425-018-0475-y DOI: https://doi.org/10.1186/s40425-018-0475-y
Poduje S, Brozić JM, Prkačin I, Delaš Aždajić M, Goren A. Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. Dermatol Ther 2020; 33: e13174.
https://doi.org/10.1111/dth.13174 DOI: https://doi.org/10.1111/dth.13174
Maximova N, Maestro A, Zanon D, Marcuzzi A. Rapid recovery of post nivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration. J Immunother Cancer 2020; 8: e000388.
https://doi.org/10.1136/jitc-2019-000388 DOI: https://doi.org/10.1136/jitc-2019-000388
Loyson T, Werbrouck E, Punie K, Bonne L, Vandecaveye V, Bechter O. Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report. Melanoma Res 2018; 28: 147-150.
https://doi.org/10.1097/CMR.0000000000000419 DOI: https://doi.org/10.1097/CMR.0000000000000419
Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, et al. Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies. J Clin Med 2019; 8: 762.
https://doi.org/10.3390/jcm8060762 DOI: https://doi.org/10.3390/jcm8060762
Additional Files
Published
How to Cite
License
Copyright (c) 2022 Tanja Batinac, Nika Hlača, Luka Simetić, Frane Valković, Sandra Peternel, Larisa Prpić-Massari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
